Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function
Chemical Biology & Drug Design · 2026-06 · 107 (6)
DOI: 10.1111/cbdd.70332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 31.05.2026. Verfasst von Ewelina Stefaniak und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Imperial College London, Molecular Sciences Research Hub, London, UK. Hauptthemen laut MEDLINE: alpha-Synuclein, Mitochondria, Oligopeptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Leverhulme Trust, Biotechnology and Biological Sciences Research Council, Horizon 2020 Framework Programme.
Abstract (Originalsprache)
Membrane binding and aggregation properties of α‐synuclein are closely associated with Parkinson's disease and a class of related syndromes named as synucleinopathy. This study explored the potential of SS‐31 (Elamipretide), a therapeutic tetrapeptide with alternating cationic and aromatic residues and known properties of mitochondrial inner membrane binding and oxidative stress reduction, in modulating α‐synuclein interaction with the lipid membranes and mitigating the impairment of mitochondrial function induced by α‐synuclein oligomers. It was demonstrated by both fluorescence correlation spectroscopy and fluorescence anisotropy that SS‐31 displaces both wild‐type and N‐terminal acetylated α‐synuclein from negatively charged small unilamellar vesicles in a dose‐dependent manner. Thioflavin‐T assay and transmission electron microscopy showed that SS‐31 inhibits membrane‐induced α‐synuclein aggregation and alters the morphology of α‐synuclein fibrils. Moreover, MTT assay and Seahorse Mito Stress Test indicated that SS‐31 enhances cell viability and restores impaired mitochondrial function in α‐synuclein oligomer‐treated neuroblastoma cells. Finally, confocal imaging revealed that SS‐31 hinders cellular uptake of α‐synuclein oligomers, possibly by modifying cell membrane electrostatics. These findings suggest that SS‐31 potentially attenuates α‐synuclein induced mitochondrial impairment via its interaction with the lipid membranes, justifying further development of a peptide‐based intervention against α‐synuclein mediated pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Heart and Lung Institute, Imperial College London, Molecular Sciences Research Hub, London, UK.
- Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, London, UK.
ORCID-Profile: Ewelina Stefaniak, Xucheng Yan, Liming Ying
Förderung
- The Leverhulme Trust
- Biotechnology and Biological Sciences Research Council
- Horizon 2020 Framework Programme
- Leverhulme Trust
Zitieren
APA
Stefaniak, E., Cui, B., Yan, X., Sun, K., Teng, X., & Ying, L. (2026). Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function. Chemical Biology & Drug Design, 107(6). https://doi.org/10.1111/cbdd.70332
Vancouver
Stefaniak E, Cui B, Yan X, Sun K, Teng X, Ying L. Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function. Chemical Biology & Drug Design. 2026;107(6). doi:10.1111/cbdd.70332
BibTeX
@article{Stefaniak2026,
author = {Stefaniak, Ewelina and Cui, Beiyuan and Yan, Xucheng and Sun, Kexin and Teng, Xiangyu and Ying, Liming},
title = {Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {6},
doi = {10.1111/cbdd.70332}
}
EUVIMED